Adenoviral expression of calmodulin antisense reduces hypertrophy in cultured cardiomyocytes.
Sustained myocardial hypertrophy is associated with an increased risk of sudden death and progression to heart failure. Multiple signal pathways are involved in cardiac hypertrophy and understanding their interaction may point to new therapeutic targets. In this work, we tested the hypothesis that adenovirus-mediated calmodulin (CaM) antisense expression will reduce the intracellular availability of CaM and inhibit the hypertrophic response. Three recombinant adenoviruses were constructed: AdASCaM, containing the AntiSense sequence of CaM and the enhanced green fluorescent protein (GFP) coding sequence; AdCaM, containing the coding sequence of CaM and the GFP sequence; and the AdGFP, containing the GFP coding sequence. Neonatal rat ventricular cardiomyocytes were infected with AdASCaM, AdCaM, or AdGFP and stimulated with phenylephrine (PE, 50 microM) or angiotensin II (AngII, 10 microM) for 48 h and cell surface area measured with planimetry. After PE treatment, the surface areas of cardiomyocytes infected with AdASCaM or AdGFP were 411 +/- 174.3 micro(2) and 832.6 +/- 372.3 micro(2), respectively (P < 0.01). After AngII treatment, the surface areas of cardiomyocytes infected with AdASCaM or AdGFP were 441.5 +/- 149.2 micro(2) and 726 +/- 328.3 micro(2), respectively (P < 0.01). Adenoviral expression of the CaM antisense (AdASCaM) significantly inhibited PE or AngII-induced cardiomyocyte hypertrophy. Cardiomyocytes infected with the AdCaM showed increased area when compared with those infected with the AdGFP. These results suggest that adenovirus-mediated changes in CaM expression may alter hypertrophy in cardiac myocytes.
Arruda
Ligia H
LH
Postgraduate Program in Biotechnology, University of São Paulo, and Center of Biomedical Technology, Bioengineering Division of the Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
Cestari
Idágene A
IA
Leirner
Adolfo A
AA
Cestari
Ismar N
IN
D000256:Adenoviridae / Q000235:genetics*; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D002147:Calmodulin / Q000096:biosynthesis* / Q000235:genetics; D049108:Cell Enlargement / Q000187:drug effects; D002478:Cells, Cultured; D005822:Genetic Vectors; D006352:Heart Ventricles / Q000166:cytology; D032383:Myocytes, Cardiac / Q000378:metabolism / Q000473:pathology*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D010656:Phenylephrine / Q000494:pharmacology; D051381:Rats; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D002147:Calmodulin; D016376:Oligonucleotides, Antisense; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D010656:Phenylephrine